Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(8%)
Results Posted
0%(0 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_4
2
17%
Ph not_applicable
3
25%
Ph phase_2
1
8%
Ph phase_3
6
50%

Phase Distribution

0

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
6(50.0%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
3(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(3)
Terminated(3)
Other(5)

Detailed Status

unknown5
Completed3
Terminated2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (8.3%)
Phase 36 (50.0%)
Phase 42 (16.7%)
N/A3 (25.0%)

Trials by Status

withdrawn18%
recruiting18%
terminated217%
completed325%
unknown542%

Recent Activity

1 active trials
Showing 5 of 12
unknownnot_applicable

Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)

NCT06199843
unknownphase_3

Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis

NCT04159870
unknownphase_3

Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

NCT04746937
recruitingphase_3

Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

NCT04161768
completednot_applicable

Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis

NCT03702426
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06199843Not Applicable

Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)

Unknown
NCT04159870Phase 3

Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis

Unknown
NCT04746937Phase 3

Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

Unknown
NCT04161768Phase 3

Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Recruiting
NCT03702426Not Applicable

Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis

Completed
NCT02120196Phase 3

Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Unknown
NCT01542801Phase 4

Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention

Completed
NCT00362752Phase 2

A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome

Completed
NCT01037959Phase 3

Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure

Terminated
NCT01527019Phase 3

Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)

Withdrawn
NCT01039545Phase 4

Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.

Terminated
NCT00163982Not Applicable

Vasoactive Peptides in Portal Pressure

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12